Age-related macular degeneration: suitability of optogenetic therapy for geographic atrophy
Age-related macular degeneration (AMD) is a growing public health concern given the aging population and it is the leading cause of blindness in developed countries, affecting individuals over the age of 55 years. AMD affects the retinal pigment epithelium (RPE) and Bruch’s membrane in the macula, l...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Frontiers Media
2024
|
| _version_ | 1811140229486084096 |
|---|---|
| author | Borchert, GA Shamsnajafabadi, H Ng, BWJ Xue, K De Silva, SR Downes, SM MacLaren, RE Cehajic-Kapetanovic, J |
| author_facet | Borchert, GA Shamsnajafabadi, H Ng, BWJ Xue, K De Silva, SR Downes, SM MacLaren, RE Cehajic-Kapetanovic, J |
| author_sort | Borchert, GA |
| collection | OXFORD |
| description | Age-related macular degeneration (AMD) is a growing public health concern given the aging population and it is the leading cause of blindness in developed countries, affecting individuals over the age of 55 years. AMD affects the retinal pigment epithelium (RPE) and Bruch’s membrane in the macula, leading to secondary photoreceptor degeneration and eventual loss of central vision. Late AMD is divided into two forms: neovascular AMD and geographic atrophy (GA). GA accounts for around 60% of late AMD and has been the most challenging subtype to treat. Recent advances include approval of new intravitreally administered therapeutics, pegcetacoplan (Syfovre) and avacincaptad pegol (Iveric Bio), which target complement factors C3 and C5, respectively, which slow down the rate of enlargement of the area of atrophy. However, there is currently no treatment to reverse the central vision loss associated with GA. Optogenetics may provide a strategy for rescuing visual function in GA by imparting light-sensitivity to the surviving inner retina (i.e., retinal ganglion cells or bipolar cells). It takes advantage of residual inner retinal architecture to transmit visual stimuli along the visual pathway, while a wide range of photosensitive proteins are available for consideration. Herein, we review the anatomical changes in GA, discuss the suitability of optogenetic therapeutic sensors in different target cells in pre-clinical models, and consider the advantages and disadvantages of different routes of administration of therapeutic vectors. |
| first_indexed | 2024-09-25T04:18:40Z |
| format | Journal article |
| id | oxford-uuid:48780c75-a0c5-4f3e-904b-db459fa06d45 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-09-25T04:18:40Z |
| publishDate | 2024 |
| publisher | Frontiers Media |
| record_format | dspace |
| spelling | oxford-uuid:48780c75-a0c5-4f3e-904b-db459fa06d452024-07-29T19:33:50ZAge-related macular degeneration: suitability of optogenetic therapy for geographic atrophyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:48780c75-a0c5-4f3e-904b-db459fa06d45EnglishJisc Publications RouterFrontiers Media2024Borchert, GAShamsnajafabadi, HNg, BWJXue, KDe Silva, SRDownes, SMMacLaren, RECehajic-Kapetanovic, JAge-related macular degeneration (AMD) is a growing public health concern given the aging population and it is the leading cause of blindness in developed countries, affecting individuals over the age of 55 years. AMD affects the retinal pigment epithelium (RPE) and Bruch’s membrane in the macula, leading to secondary photoreceptor degeneration and eventual loss of central vision. Late AMD is divided into two forms: neovascular AMD and geographic atrophy (GA). GA accounts for around 60% of late AMD and has been the most challenging subtype to treat. Recent advances include approval of new intravitreally administered therapeutics, pegcetacoplan (Syfovre) and avacincaptad pegol (Iveric Bio), which target complement factors C3 and C5, respectively, which slow down the rate of enlargement of the area of atrophy. However, there is currently no treatment to reverse the central vision loss associated with GA. Optogenetics may provide a strategy for rescuing visual function in GA by imparting light-sensitivity to the surviving inner retina (i.e., retinal ganglion cells or bipolar cells). It takes advantage of residual inner retinal architecture to transmit visual stimuli along the visual pathway, while a wide range of photosensitive proteins are available for consideration. Herein, we review the anatomical changes in GA, discuss the suitability of optogenetic therapeutic sensors in different target cells in pre-clinical models, and consider the advantages and disadvantages of different routes of administration of therapeutic vectors. |
| spellingShingle | Borchert, GA Shamsnajafabadi, H Ng, BWJ Xue, K De Silva, SR Downes, SM MacLaren, RE Cehajic-Kapetanovic, J Age-related macular degeneration: suitability of optogenetic therapy for geographic atrophy |
| title | Age-related macular degeneration: suitability of optogenetic therapy for geographic atrophy |
| title_full | Age-related macular degeneration: suitability of optogenetic therapy for geographic atrophy |
| title_fullStr | Age-related macular degeneration: suitability of optogenetic therapy for geographic atrophy |
| title_full_unstemmed | Age-related macular degeneration: suitability of optogenetic therapy for geographic atrophy |
| title_short | Age-related macular degeneration: suitability of optogenetic therapy for geographic atrophy |
| title_sort | age related macular degeneration suitability of optogenetic therapy for geographic atrophy |
| work_keys_str_mv | AT borchertga agerelatedmaculardegenerationsuitabilityofoptogenetictherapyforgeographicatrophy AT shamsnajafabadih agerelatedmaculardegenerationsuitabilityofoptogenetictherapyforgeographicatrophy AT ngbwj agerelatedmaculardegenerationsuitabilityofoptogenetictherapyforgeographicatrophy AT xuek agerelatedmaculardegenerationsuitabilityofoptogenetictherapyforgeographicatrophy AT desilvasr agerelatedmaculardegenerationsuitabilityofoptogenetictherapyforgeographicatrophy AT downessm agerelatedmaculardegenerationsuitabilityofoptogenetictherapyforgeographicatrophy AT maclarenre agerelatedmaculardegenerationsuitabilityofoptogenetictherapyforgeographicatrophy AT cehajickapetanovicj agerelatedmaculardegenerationsuitabilityofoptogenetictherapyforgeographicatrophy |